Voya Investment Management LLC purchased a new stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 19,882 shares of the biopharmaceutical company’s stock, valued at approximately $125,000.

A number of other hedge funds have also modified their holdings of CRBP. Bank of New York Mellon Corp boosted its position in Corbus Pharmaceuticals Holdings by 7.7% in the 1st quarter. Bank of New York Mellon Corp now owns 21,102 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 1,511 shares during the period. Vanguard Group Inc. boosted its position in Corbus Pharmaceuticals Holdings by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock valued at $10,357,000 after buying an additional 71,419 shares during the period. Geode Capital Management LLC boosted its position in Corbus Pharmaceuticals Holdings by 16.5% in the 1st quarter. Geode Capital Management LLC now owns 201,177 shares of the biopharmaceutical company’s stock valued at $1,659,000 after buying an additional 28,492 shares during the period. Credit Suisse AG purchased a new position in Corbus Pharmaceuticals Holdings in the 1st quarter valued at approximately $157,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in Corbus Pharmaceuticals Holdings in the 2nd quarter valued at approximately $469,000. 28.66% of the stock is owned by institutional investors.

In related news, Director David P. Hochman purchased 5,000 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $6.90 per share, with a total value of $34,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David P. Hochman purchased 10,000 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Friday, November 10th. The stock was bought at an average cost of $7.08 per share, with a total value of $70,800.00. Following the completion of the transaction, the director now owns 459,500 shares of the company’s stock, valued at $3,253,260. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 25,336 shares of company stock valued at $175,632. 11.90% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/24/voya-investment-management-llc-purchases-new-stake-in-corbus-pharmaceuticals-holdings-inc-crbp.html.

Several equities analysts have commented on CRBP shares. ValuEngine cut shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. BidaskClub cut shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Noble Financial lifted their price objective on shares of Corbus Pharmaceuticals Holdings from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $24.00 price objective on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Corbus Pharmaceuticals Holdings presently has an average rating of “Hold” and a consensus target price of $20.75.

Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) opened at $7.10 on Friday. Corbus Pharmaceuticals Holdings, Inc. has a 1 year low of $5.30 and a 1 year high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The firm had revenue of $0.80 million during the quarter. research analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post -0.61 earnings per share for the current fiscal year.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Want to see what other hedge funds are holding CRBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP).

Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.